摘要
目的:探讨卡瑞利珠单抗联合新辅助化疗治疗局部晚期食管癌的临床效果。方法:回顾性收集2019年6月~2023年6月期间某院收治的71例局部晚期食管癌患者的临床资料,根据不同治疗方式分为对照组(n=35,采用新辅助化疗治疗)和观察组(n=36,采用卡瑞利珠单抗+新辅助化疗治疗),均于术前治疗2个疗程。比较两组患者临床疗效、R0切除率、肿瘤标志物(癌胚抗原、糖类抗原19-9和鳞状上皮细胞癌抗原)水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+))及不良反应发生情况。结果:术前治疗2个疗程后,观察组患者治疗缓解率(52.78%)高于对照组(28.57%,P<0.05);两组患者癌胚抗原、糖类抗原19-9和鳞状上皮细胞癌抗原水平均降低,且观察组低于对照组(P<0.05)。观察组患者CD3^(+)和CD4^(+)水平均高于对照组,CD8^(+)水平低于对照组(P<0.05)。观察组患者术后R0切除率(88.89%)高于对照组(68.57%,P<0.05)。治疗期间,两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:卡瑞利珠单抗联合新辅助化疗治疗可提高局部晚期食管癌患者的临床疗效和手术切除效果,降低肿瘤标志物水平,改善免疫功能,且未增加不良反应的发生风险。
Objective:To investigate the clinical efficacy of camrelizumab combined with neoadjuvant chemotherapy in treating locally advanced oesophageal cancer.Methods:The data of 71 patients with locally advanced oesophageal cancer admitted to a hospital between June 2019 and June 2023 were retrospectively collected.The patients were assigned to the control group(n=35,treated with neoadjuvant chemotherapy)and observation group(n=36,treated with camrelizumab+neoadjuvant chemotherapy)according to different treatment methods.All patients received two courses of treatment before surgery.The clinical efficacy,R0 resection rate,tumor markers(carcinoembryonic antigen,carbohydrate antigen 19-9,squamous cell carcinoma antigen),immune function parameters(CD3^(+),CD4^(+),CD8^(+))and adverse reactions were compared between the two groups.Results:After two courses of preoperative treatment,the treatment remission rate of the observation group(52.78%)was higher than that of the control group(28.57%,P<0.05).The levels of carcinoembryonic antigen,carbohydrate antigen 19-9 and squamous cell carcinoma antigen were decreased in both groups,with the observation group showing lower levels than the control group(P<0.05).The levels of CD3^(+)and CD4^(+)were higher in the observation group than in the control group,while CD8^(+)levels were lower in the observation group than in the control group(P<0.05).The R0 resection rate of patients in the observation group after surgery(88.89%)was higher than that of the control group(68.57%,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups during the treatment(P>0.05).Conclusion:Camrelizumab combined with neoadjuvant chemotherapy can enhance clinical efficacy and surgical resection outcomes in patients with locally advanced oesophageal cancer,reducing tumor marker levels,improving immune function,without increasing the risk of adverse reactions.
作者
孔晓煌
何晓娟
王梦雪
户安喜
连欢欢
张涛
魏创业
韩高扬
张仁锋
王金龙
KONG Xiao-huang;HE Xiao-juan;WANG Meng-xue;HU An-xi;LIAN Huan-huan;ZHANG Tao;WEI Chuang-ye;HAN Gao-yang;ZHANG Ren-feng;WANG Jin-long(Department of Thoracic Surgery,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,China;Department of Pathology,the Third People's Hospital of Henan Province,Zhengzhou 450000,China;Department of Disease Control and Prevention,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《中国合理用药探索》
2025年第11期68-73,共6页
Chinese Journal of Rational Drug Use
关键词
卡瑞利珠单抗
新辅助化疗
局部晚期食管癌
肿瘤标志物
免疫功能
camrelizumab
neoadjuvant chemotherapy
locally advanced oesophageal cancer
tumor markers
immune function
